Hyperfine - Class A opened lower at $0.69, compared with its previous close of $0.71. In the last trading session, the stock traded between $0.67 and $0.70. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Hyperfine - Class A is now worth
$ 7.29
Resulting in a loss of
$ 92.71 (92.71%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.04 (-5.81%)
Day High
$0.70
Day Low
$0.67
Day Open
$0.69
Prev Close
$0.71
Volume
4,63,436
1W Return
-11.02%
1M Return
-26.13%
3M Return
-30.14%
6M Return
-61.71%
1Y Return
-39.09%
Fundamentals
Market Cap ($ Mn)
61
PE Ratio
-
PB Ratio
2.40
PEG Ratio
-
ROE
-91.14%
ROCE
-88.11%
EPS (TTM)
$-0.06
Investment Returns
1 Week
-11.02%
1 Month
-26.13%
3 Months
-30.14%
6 Months
-61.71%
9 Months
-39.09%
Financials
Quarterly
All values in $ Mn
2.7
Jun 25
3.4
Sep 25
5.3
Dec 25
3.9
Mar 26
3.9
Jun 26
6.0
Sep 26
Updates
10Nov
Hyperfine files prospectus for $150 million mixed shelf offering
Hyperfine Inc. filed a prospectus for a $150 million mixed shelf offering. The registration covers common stock, preferred stock, debt, and warrants. Securities may be issued from time to time at future market-determined prices.
3 days ago
10Nov
Hyperfine posts record Q3 revenue of $6 million, up 73% YoY
Revenue reached a record $6 million, up 73% YoY and 53% QoQ. Gross margin hit a record 56.7%, up 290 bps YoY. Net cash burn fell 29% sequentially to $5.6 million. Full-year revenue guidance of $20-22 million reaffirmed.
3 days ago
8Oct
Hyperfine FY26 Results: Sales guidance affirmed at $20M-$22M
Hyperfine Inc affirmed FY2026 sales guidance of $20.000 million to $22.000 million. The guidance range includes the analyst estimate of $20.163 million. Upper bound of guidance exceeds the analyst estimate by $1.837 million.
1mo ago
31Aug
Hyperfine joins Lake Street Capital Markets growth conference
Hyperfine plans to participate in the Lake Street Capital Markets conference on September 10. Management will host in-person meetings with investors during the event. The company markets the Swoop system, an FDA-cleared portable MRI device.
2mo ago
26Aug
Hyperfine completes 3,000 Swoop scans; NEURO PMR study published
Hyperfine published NEURO PMR study results in Journal of Neuroimaging. Study showed 92% concordance with high-field MRI for structural abnormalities. Company completed over 3,000 Swoop brain MRI scans in first year of office launch. Patients preferred portable MRI by a four-to-one margin over high-field systems.
2mo ago
20Aug
Hyperfine gets FDA clearance for Optive AI software update
Hyperfine secured FDA clearance for its second Optive AI software package since launching the Swoop system in mid-2025. The update improves noise cancellation for point-of-care use and adds an isotropic T1 sequence for better spatial visualization. A U.S. rollout is scheduled for September.
